This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of fatigue and chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for early stage breast cancer. Patients undergoing chemotherapy may experience fatigue or nausea as a result of their treatment. Known risk factors for fatigue and CIN do not explain the differences in fatigue and CIN occurrence between patients, but changes in the functions of the gut microbiome may be related to the occurrence of fatigue and CIN. This study collects stool samples from breast cancer patients before and after chemotherapy to evaluate how changes in the microbiome may be associated with fatigue and CIN.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of patients approached
Timeframe: Up to 24 months
Number of patients enrolled
Timeframe: Up to 24 months
Number of patients who completed the questionnaires at both assessments
Timeframe: At baseline and 3-5 days after initiation of chemotherapy
Number of patients who provided stool samples at both assessments
Timeframe: At baseline and 3-5 days after initiation of chemotherapy
Bacterial composition of stool samples
Timeframe: Up to study completion
Differences in demographic between patients who do and do not report fatigue and CIN
Timeframe: Up to study completion
Differences in clinical characteristics between patients who do and do not report CIN
Timeframe: Up to study completion
Differences in comorbidities between patients who do and do not report CIN
Timeframe: Up to study completion